Astal Laboratories Ltd (ASTALLTD) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Astal Laboratories Ltd on NSE and BSE, with an AI summary of each filing.
Submission of Voting Results.
Annual General Meeting · 01 Oct 2026, 12:45 am
Astal Laboratories Approves All AGM Resolutions with Overwhelming Shareholder Support Astal Laboratories Limited announced the voting results for its 33rd Annual General Meeting held on 29th Sep'26. Shareholders approved all three ordinary resolutions with near-unanimous majorities. Key approvals included the adoption of standalone and consolidated audited financial statements for the fiscal year ended 31st Mar'26, both securing ~100% of polled votes in favor (20,348,067 votes). Additionally, the reappointment of Mr. Maggidi Venkatesh as Non-Executive Director was approved with 99.9994% favorable votes. Overall voter turnout represented 46.46% of total outstanding shares across 20.35M polled votes.
Submission of voting Results with scrutinizers report.
Annual General Meeting · 01 Oct 2026, 12:41 am
Astal Laboratories Approves All AGM Resolutions with Overwhelming Majority Astal Laboratories Limited announced the voting results for its 33rd Annual General Meeting held on 29th Sep'26. Shareholders approved all three ordinary resolutions with near-unanimous majorities (~100% votes in favor). The approved items include the adoption of the standalone and consolidated audited financial statements for the fiscal year ended 31st Mar'26, as well as the reappointment of Mr. Maggidi Venkatesh as Non-Executive Director. Total voter turnout stood at 46.46% of outstanding shares (20,348,068 votes polled), with promoter participation at 100%.
Attached.
Change in Auditor · 30 Sept 2026, 5:48 pm
Astal Laboratories Announces Auditor Appointments for Material Subsidiary Astal Laboratories Limited's material wholly-owned subsidiary, Sriven Pharmachem India Private Limited, approved key auditor appointments at its board meeting on 28th Sep'26. M/s Avnesh Jain & Co. was appointed as Cost Auditor, and M/s Mahendra Khandelwal & Co. as Secretarial Auditor for FY 2026-27. Additionally, Mr. Balayogiswara Rao Peddinti was appointed as Internal Auditor effective 28th Sep'26. The appointments aim to ensure regulatory compliance under the Companies Act, 2013, and strengthen the subsidiary's corporate governance and financial controls.
Attached
Others (Uncategorized) · 30 Sept 2026, 5:46 pm
Astal Laboratories Announces Company Secretary Appointment for Subsidiary Sriven Pharmachem Astal Laboratories Limited informed exchanges that the Board of Directors of its material wholly-owned subsidiary, Sriven Pharmachem India Private Limited (SPIPL), approved the appointment of Ms. Ambika Kedia as Company Secretary, effective 28th Sep'26. The appointment was finalized during SPIPL's board meeting held on 28th Sep'26 to comply with the provisions of the Companies Act, 2013. Ms. Kedia is a qualified Company Secretary with functional experience in regulatory compliance, corporate secretarial operations, statutory filings, and board governance.
Submission of outcome of 33rd Annual General Meeting.
Annual General Meeting · 29 Sept 2026, 11:31 pm
Submission of Intimation under SEBI (PIT) Regulations, 2015.
Others (Uncategorized) · 11 Sept 2026, 8:41 pm
Aceso Research Labs Acquires Equity Shares in Astal Laboratories via Open Market Astal Laboratories Limited reported an insider trading disclosure regarding its promoter, Aceso Research Labs LLP. The promoter acquired 25,417 equity shares of Astal Laboratories through an open-market transaction on BSE for a total consideration of Rs 19,98,812. The acquisition took place between 24th Aug'26 and 8th Sep'26. Following this purchase, Aceso Research Labs' holding in the company increased from 19,85,595 equity shares to 20,11,012 equity shares. Intimation was submitted to the stock exchange on 11th Sep'26.
Attached.
Annual General Meeting · 08 Sept 2026, 3:08 am
Astal Laboratories Schedules 33rd AGM and Dispatches FY26 Annual Report Astal Laboratories Limited has issued notice for its 33rd Annual General Meeting (AGM) scheduled for 29th Sep'26 via Video Conferencing. The cut-off date to determine shareholder voting eligibility is 22nd Sep'26, with the e-voting window open from 26th Sep'26 (9:00 AM IST) to 29th Sep'26 (5:00 PM IST). Register of Members and Share Transfer Books will remain closed from 23rd Sep'26 to 29th Sep'26. The company is dispatching web access details for its FY26 Annual Report and AGM notice to unregistered email holders.
Submission of 33rd AGM Notice.
Annual General Meeting · 08 Sept 2026, 3:04 am
Submission of Annual Report for the financial year ended March 31, 2026.
Others (Uncategorized) · 08 Sept 2026, 2:57 am
Submission of Intimation of AGM.
Annual General Meeting · 06 Sept 2026, 3:36 am
Submission of intimation of Appointment of Cost Auditor.
Change in Auditor · 06 Sept 2026, 3:33 am
Astal Laboratories Appoints Avnesh Jain & Co. as FY27 Cost Auditors Astal Laboratories Limited announced that its Board of Directors approved the appointment of M/s Avnesh Jain & Co., Cost Accountants (FRN: 101048), as the company's Cost Auditors for FY26-27 during its meeting on 4th Sep'26. The firm has no relationships with any directors, Key Managerial Personnel, or their relatives.
Submission of outcome of the meeting of the Board of Directors.
Outcome · 04 Sept 2026, 11:57 pm
Astal Laboratories Board Approves AGM Date, Book Closure, and Auditor Appointment Astal Laboratories Limited's Board of Directors approved the Board Report for the financial year ended 31st Mar'26 and appointed M/s Avnesh Jain & Co. as Cost Auditors for FY27. The 33rd Annual General Meeting is scheduled for 29th Sep'26 via video conferencing. The register of members and share transfer books will remain closed from 23rd Sep'26 to 29th Sep'26. The cut-off date to determine e-voting eligibility is set for 22nd Sep'26, with M/s. Mahendra Khandelwal & Co. appointed as scrutinizer.
Astal Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/09/2026 ,inter alia, to consider and approve 1. To Consider & to approve ....
Intimation · 31 Aug 2026, 11:05 pm
Submission of Statement of Deviation & Variation
Others (Uncategorized) · 15 Aug 2026, 12:59 am
Astal Laboratories Reports No Deviation in Utilization of Raised Funds for QE Jun'26 Astal Laboratories reported no deviation or variation in the utilization of funds raised for the quarter ended 30th Jun'26. The company reviewed three separate fundraises: Rs. 306.00 lakhs from 14th Jan'26, Rs. 441.00 lakhs from 12th May'26, and Rs. 33.99 lakhs from 25th May'26. Funds were raised for capex, working capital, and corporate purposes. As of the quarter-end, Rs. 306.00 lakhs, Rs. 441.00 lakhs, and Rs. 8.99 lakhs, respectively, from each tranche were utilized, with zero deviation from their stated objectives.
Submission of Financial Results for the quarter ended June 30, 2026.
Financial Result · 15 Aug 2026, 12:03 am
Astal Labs Q1 Standalone PAT Surges 77% YoY; Revenue Up 56% Astal Laboratories reported strong standalone results for Q1 ending 30-Jun-26. Revenue from operations grew 56.0% YoY to Rs. 3,951.41 lakhs, though it fell 3.4% QoQ. Profit After Tax (PAT) surged 77.4% YoY to Rs. 370.69 lakhs and was up 240.4% QoQ. Basic EPS stood at Rs. 0.861, down from Rs. 2.126 YoY but up from Rs. 0.288 QoQ. On a consolidated basis, Q1 PAT was Rs. 942.17 lakhs versus Rs. 767.99 lakhs QoQ, while revenue was Rs. 10,093.58 lakhs versus Rs. 13,404.90 lakhs QoQ.
Submission of Outcome of Board Meeting.
Outcome · 14 Aug 2026, 11:51 pm
Astal Laboratories Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) ■ Revenue: 10,094 (-24.7% QoQ) ■ EBITDA: 1,225 (+20.2% QoQ) ■ EBITDA Margin (%): 12.1 (+453 bps QoQ) ■ PAT: 942 (+22.7% QoQ) ■ EPS (INR): 2.18 (+11.9% QoQ)
Astal Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Prior intimation of Board ....
Intimation · 14 Aug 2026, 5:30 am
Astal Laboratories to Consider Q1FY27 Financial Results on 14-Aug-'26 Astal Laboratories has scheduled a Board of Directors meeting on 14-Aug-'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter ended 30-Jun-'26. The company also announced that the trading window for designated persons has been closed from 01-Jul-'26 until 48 hours after the board meeting's conclusion, in compliance with SEBI insider trading regulations.
Outcome of board meeting held on today i.e. 29th June, 2026.
Others (Uncategorized) · 29 Jun 2026, 4:38 pm
Astal Laboratories Board Approves Major M&A and Fundraising Plans Astal Laboratories' Board, on 29th Jun'26, authorized plans to acquire USFDA, EU-GMP, or WHO-GMP compliant pharmaceutical manufacturing units in India to expand capacity. The company's Whole-time Director will lead these M&A discussions. Additionally, the Board approved raising up to Rs.300 Crore through various instruments, including convertible debentures (CCDs), convertible preference shares (CCPS), or non-convertible debentures (NCDs) via private placement. The CFO is authorized to negotiate with prospective investors and financial institutions for this capital raise, pending shareholder approval.
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Others (Uncategorized) · 22 Jun 2026, 10:47 pm
Astal Laboratories Confirms It Is Not a Large Corporate for FY26 Astal Laboratories Ltd (ASTALLTD) has confirmed to the BSE that it does not fall under the Large Corporate (LC) framework for the financial year 2025-2026, as per SEBI regulations. This follows an earlier submission on 23-Apr-25. Consequently, the provisions of the circular, which mandate certain borrowing through debt instruments for LCs, are not applicable to the company. The disclosure was filed with the exchange on 22-Jun-26.
Intimation of authorization of KMPs under regulation 30 (5) of SEBI (LODR), Regulations, 2015.
Others (Uncategorized) · 01 Jun 2026, 6:02 pm
Astal Laboratories Authorizes Key Personnel for Materiality Disclosures Astal Laboratories announced on 01-Jun'26 that its Board of Directors has authorized specific Key Managerial Personnel (KMPs) to determine the materiality of events and make necessary disclosures to the stock exchange. The authorized individuals are Sudheer Karna Kankanala (Whole-time Director), Balayogiswara Rao Peddinti (CFO), and Mahendra Kumar (Company Secretary & Compliance Officer). This action is in compliance with Regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, streamlining the company's disclosure process.
Internal Auditor appointment for the financial year 2026-27.
Change in Auditor · 31 May 2026, 10:57 pm
Astal Laboratories Re-appoints V R P S & Co. as Internal Auditor Astal Laboratories' Board of Directors approved the re-appointment of M/s V R P S & Co., Chartered Accountants (FRN: 006340S), as the company's Internal Auditor for the financial year 2026-27. The decision was made at the board meeting on 30th May'26 to comply with the Companies Act 2013 and SEBI listing regulations. The appointed firm is not related to any directors or Key Managerial Personnel of the company.
Financial Results for quarter and year ended March 31, 2026
Financial Result · 31 May 2026, 4:24 am
Astal Laboratories Reports Q4 & FY26 Results with Strong YoY Revenue Growth Astal Laboratories reported consolidated Q4 FY26 results with revenue at ₹13,414.52 lakhs, up 470% YoY, and a net profit of ₹767.99 lakhs, up 179.9% YoY. Sequentially, revenue grew 156.6% while net profit surged 225.8%. For the full year ended 31 Mar'26, consolidated revenue increased 287.4% YoY to ₹24,934.88 lakhs, and net profit grew 64.8% YoY to ₹1,470.94 lakhs. The company reported a full-year basic EPS of ₹8.622, down from ₹9.080 in FY25. The auditor issued an unmodified opinion.
Statement of Deviation and variation
Others (Uncategorized) · 31 May 2026, 2:53 am
Astal Laboratories Reports No Deviation in Fund Use for Q4FY26 Astal Laboratories reported no deviation in the utilization of funds for the quarter ended 31 Mar'26. The company did not raise any cash through its preferential issue on 14 Jan'26 for the acquisition of Sriven Pharmachem; equity shares were issued via a share swap. A separate fundraise of Rs. 306 Lakhs for long-term funding requirements was also reported, with Rs. 286 Lakhs utilized for capital expenditure, working capital, and general corporate purposes, showing no deviation from its stated objectives. The filings were reviewed by the Audit Committee on 30 May'26.
Audited standalone and consolidated financial results for the quarter and financial year ended March. 31, 2026.
Financial Result · 31 May 2026, 2:41 am
Astal Labs Q4FY26 Consolidated Net Profit Jumps 180% YoY to ₹768 Lakhs Astal Laboratories reported robust consolidated results for Q4FY26, with net profit surging 180% YoY to ₹767.99 lakhs from ₹274.48 lakhs. Revenue from operations grew an impressive 471% YoY to ₹13,404.90 lakhs. For the full year FY26, consolidated net profit increased 65% YoY to ₹1,470.94 lakhs, while revenue climbed 288% to ₹24,912.73 lakhs. The board approved these results on 30-May'26. The company operates a single segment of manufacturing and trading Active Pharmaceutical Ingredients (APIs).
Outcome of Board Meeting held on Saturday, 30th May, 2026.
Outcome · 31 May 2026, 2:33 am
Astal Laboratories Ltd - Financial Result for the Quarter ended 31st Mar'26 (Consolidated, INR Lakh) ■ Revenue: 13,405 (+471.2% YoY | +156.6% QoQ) ■ EBITDA: 1,019 (+143.6% YoY | +187.0% QoQ) ■ EBITDA Margin (%): 7.6 (-1022 bps YoY | +80 bps QoQ) ■ PAT: 768 (+179.8% YoY | +225.8% QoQ) ■ EPS (INR): 0.28 (-84.4% YoY | -84.2% QoQ)